Literature DB >> 32131463

Type III Secretion Effectors with Arginine N-Glycosyltransferase Activity.

Juan Luis Araujo-Garrido1, Joaquín Bernal-Bayard1, Francisco Ramos-Morales1.   

Abstract

Type III secretion systems are used by many Gram-negative bacterial pathogens to inject proteins, known as effectors, into the cytosol of host cells. These virulence factors interfere with a diverse array of host signal transduction pathways and cellular processes. Many effectors have catalytic activities to promote post-translational modifications of host proteins. This review focuses on a family of effectors with glycosyltransferase activity that catalyze addition of N-acetyl-d-glucosamine to specific arginine residues in target proteins, leading to reduced NF-κB pathway activation and impaired host cell death. This family includes NleB from Citrobacter rodentium, NleB1 and NleB2 from enteropathogenic and enterohemorrhagic Escherichia coli, and SseK1, SseK2, and SseK3 from Salmonella enterica. First, we place these effectors in the general framework of the glycosyltransferase superfamily and in the particular context of the role of glycosylation in bacterial pathogenesis. Then, we provide detailed information about currently known members of this family, their role in virulence, and their targets.

Entities:  

Keywords:  Citrobacter; Escherichia; NleB; Salmonella; SseK; death domains; effectors; glycosyltransferases; type III secretion

Year:  2020        PMID: 32131463     DOI: 10.3390/microorganisms8030357

Source DB:  PubMed          Journal:  Microorganisms        ISSN: 2076-2607


  10 in total

Review 1.  Escherichia coli 0157:H7 virulence factors and the ruminant reservoir.

Authors:  Anna M Kolodziejek; Scott A Minnich; Carolyn J Hovde
Journal:  Curr Opin Infect Dis       Date:  2022-06-01       Impact factor: 4.968

2.  Tubulin Folding Cofactor TBCB is a Target of the Salmonella Effector Protein SseK1.

Authors:  Juan Luis Araujo-Garrido; Fernando Baisón-Olmo; Joaquín Bernal-Bayard; Francisco Romero; Francisco Ramos-Morales
Journal:  Int J Mol Sci       Date:  2020-04-30       Impact factor: 5.923

3.  Comparative genomic insights into Yersinia hibernica - a commonly misidentified Yersinia enterocolitica-like organism.

Authors:  Scott Van Nguyen; Dechamma Mundanda Muthappa; Athmanya K Eshwar; James F Buckley; Brenda P Murphy; Roger Stephan; Angelika Lehner; Séamus Fanning
Journal:  Microb Genom       Date:  2020-07-23

Review 4.  Nucleotide Sugars in Chemistry and Biology.

Authors:  Satu Mikkola
Journal:  Molecules       Date:  2020-12-06       Impact factor: 4.411

5.  Virulence-related O islands in enterohemorrhagic Escherichia coli O157:H7.

Authors:  Lingyan Jiang; Wen Yang; Xinlei Jiang; Ting Yao; Lu Wang; Bin Yang
Journal:  Gut Microbes       Date:  2021 Jan-Dec

6.  NleB/SseK-catalyzed arginine-glycosylation and enteropathogen virulence are finely tuned by a single variable position contiguous to the catalytic machinery.

Authors:  Ana García-García; Thomas Hicks; Samir El Qaidi; Congrui Zhu; Philip R Hardwidge; Jesús Angulo; Ramon Hurtado-Guerrero
Journal:  Chem Sci       Date:  2021-08-19       Impact factor: 9.825

7.  Arginine GlcNAcylation and Activity Regulation of PhoP by a Type III Secretion System Effector in Salmonella.

Authors:  Juan Xue; Yuxuan Huang; Hua Zhang; Jiaqingzi Hu; Xing Pan; Ting Peng; Jun Lv; Kun Meng; Shan Li
Journal:  Front Microbiol       Date:  2022-01-20       Impact factor: 5.640

Review 8.  Glycosylating Effectors of Legionella pneumophila: Finding the Sweet Spots for Host Cell Subversion.

Authors:  Yury Belyi; Nadya Levanova; Gunnar N Schroeder
Journal:  Biomolecules       Date:  2022-02-04

9.  Special Issue: Type III Secretion Systems in Human/Animal Pathogenic Bacteria.

Authors:  Joaquín Bernal-Bayard; Francisco Ramos-Morales
Journal:  Microorganisms       Date:  2022-07-20

Review 10.  Bacteria-Catalyzed Arginine Glycosylation in Pathogens and Host.

Authors:  Xing Pan; Jie Luo; Shan Li
Journal:  Front Cell Infect Microbiol       Date:  2020-04-28       Impact factor: 5.293

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.